Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amgen’s Repatha Unclogs Arteries in Imaging Study

By Ryan Bushey | November 16, 2016

Amgen announced good news for its cholesterol drug Repatha at the annual American Heart Association meeting taking place in New Orleans.

The drug taken in conjunction with a statin simultaneously caused a decline in artery-clogging plaques in a majority of high-risk heart patients after 18 months of treatment while also lowering levels of LDL cholesterol down to extremely low levels, reported Reuters.

Investigators running this trial featuring 968 patients compared the Repatha combination therapy against statins alone to determine the impact these treatments could have on the plaques that can play a role in causing heart attacks.

Participants in this experiment were diagnosed with symptomatic heart disease and blockages of 20 percent to 50 percent in the tested artery, according to Reuters. An ultrasound probe was placed inside the diseased artery in order to collect these plaque measurements.

Results revealed a little over 64 percent of patients taking the combination plaque therapy experienced plaque regression versus an approximate 47.3 percent of patients taking just the statin.

Amgen previously said the study was a success, but this is the first time the company reported the specific percentage of patients who experienced a decrease of the artery-clogging plaques that cause heart disease as well as identifying the magnitude of plaque regression.

Repatha belongs to a class of drugs called PCKS9 inhibitors, which have come under scrutiny for their list prices of $14,000 a year.

Insurers have restricted their coverage because of the belief that these drugs are too expensive if they can only lower cholesterol, wrote Bloomberg. However, this new data on Repatha could change the perception of insurers and pharmacy benefits potentially making it easier to access these drugs.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE